Switch theme
Sign up to access all valuation multiples
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.
1919
6.3K+
LTM Revenue $3.1B
LTM EBITDA $1.2B
$9.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shionogi has a last 12-month revenue (LTM) of $3.1B and a last 12-month EBITDA of $1.2B.
In the most recent fiscal year, Shionogi achieved revenue of $3.0B and an EBITDA of $1.5B.
Shionogi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shionogi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1B | XXX | $3.0B | XXX | XXX | XXX |
| Gross Profit | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | $1.2B | XXX | $1.5B | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 51% | XXX | XXX | XXX |
| EBIT | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EBIT Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| Net Profit | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| Net Margin | 38% | XXX | 37% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Shionogi's stock price is JPY 2408 (or $17).
Shionogi has current market cap of JPY 2.05T (or $14.1B), and EV of JPY 1.43T (or $9.8B).
See Shionogi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.8B | $14.1B | XXX | XXX | XXX | XXX | $1.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Shionogi has market cap of $14.1B and EV of $9.8B.
Shionogi's trades at 3.3x EV/Revenue multiple, and 6.3x EV/EBITDA.
Equity research analysts estimate Shionogi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shionogi has a P/E ratio of 12.0x.
See valuation multiples for Shionogi and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14.1B | XXX | $14.1B | XXX | XXX | XXX |
| EV (current) | $9.8B | XXX | $9.8B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBIT | 9.0x | XXX | 9.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.0x | XXX | 12.2x | XXX | XXX | XXX |
| EV/FCF | 12.3x | XXX | 11.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShionogi's last 12 month revenue growth is 11%
Shionogi's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Shionogi's rule of 40 is 64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shionogi's rule of X is 68% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shionogi and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 53% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | -4% | XXX | XXX | XXX |
| Rule of 40 | 64% | XXX | 64% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 68% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shionogi acquired XXX companies to date.
Last acquisition by Shionogi was XXXXXXXX, XXXXX XXXXX XXXXXX . Shionogi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Shionogi founded? | Shionogi was founded in 1919. |
| Where is Shionogi headquartered? | Shionogi is headquartered in Japan. |
| How many employees does Shionogi have? | As of today, Shionogi has 6.3K+ employees. |
| Who is the CEO of Shionogi? | Shionogi's CEO is Dr. Isao Teshirogi, PhD. |
| Is Shionogi publicy listed? | Yes, Shionogi is a public company listed on TKS. |
| What is the stock symbol of Shionogi? | Shionogi trades under 4507 ticker. |
| When did Shionogi go public? | Shionogi went public in 1949. |
| Who are competitors of Shionogi? | Similar companies to Shionogi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Shionogi? | Shionogi's current market cap is $14.1B |
| What is the current revenue of Shionogi? | Shionogi's last 12 months revenue is $3.1B. |
| What is the current revenue growth of Shionogi? | Shionogi revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Shionogi? | Current revenue multiple of Shionogi is 3.2x. |
| Is Shionogi profitable? | Yes, Shionogi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Shionogi? | Shionogi's last 12 months EBITDA is $1.2B. |
| What is Shionogi's EBITDA margin? | Shionogi's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of Shionogi? | Current EBITDA multiple of Shionogi is 7.9x. |
| What is the current FCF of Shionogi? | Shionogi's last 12 months FCF is $793M. |
| What is Shionogi's FCF margin? | Shionogi's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Shionogi? | Current FCF multiple of Shionogi is 12.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
